ACOR: Acorda Therapeutics, Inc. - Summary | Jitta
Jitta Wealth
NEW
Log in
Sign up
×
Log in

Acorda Therapeutics, Inc.

NASDAQ:ACOR

SummaryFactSheetFinancial
Notice
Stock data is unavailable or the company’s delisted.
Price
$0.01
Loss Chance
48.2%
2.03JITTA SCORE
99.83%Under Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Alkermes plc
NASDAQ:ALKS
5.18
$42.27
260.22%
Catalyst Pharmaceuticals
NASDAQ:CPRX
6.36
$31.27
42.83%
Gilead Sciences
NASDAQ:GILD
6.77
$131.10
0.94%
Halozyme Therapeutics
NASDAQ:HALO
6.26
$68.14
56.62%
Incyte Corporation
NASDAQ:INCY
5.05
$95.59
15.03%
Jitta Factors
Growth Opportunity (37)
Recent Business Performance (53)
Financial Strength (16)
Return to Shareholders (2)
Competitive Advantage (34)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2023
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
2.03
99.83%
2.22
137.59%
3.06
159.47%
Biotechnology
5.18
260.22%
6.36
42.83%
6.77
0.94%
COMPANY DESCRIPTION
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson’s disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
www.acorda.com
About UsCareersHelp CenterLibraryTermsPrivacyContact UsPress

Jitta Dot Com Co., Ltd. is the owner of the copyright of JITTA SCORE, JITTA LINE, JITTA SIGNS, JITTA FACTORS, JITTA LOSS CHANCE and JITTA RANKING. By accessing or using Jitta, you agree to comply with our Terms of Use and agree not to redistribute the information.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Any historical returns, backtest statistics or probability projections may not reflect future performance. Neither Jitta nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Fundamental data of companies, historical data, daily updates, financial statements, dividend data and index data are provided by S&P Global Market Intelligence. All stock prices are updated at the end of the day.